Abstract
Percutaneous coronary angioplasty (PCI) has become a routine treatment in symptomatic patients with coronary artery disease. The use of new generation drug eluting stents (DES) and dual antiplatelet therapy has significantly improved treatment outcomes and increased patients' safety by reducing the risk of stent thrombosis. The goal of this study was to assess whether high on treatment platelet reactivity (HTPR), despite clopidogrel treatment, measured with Multiplate Electrode Aggregometer (MEA) is associated with the risk of adverse ischemic cerebral events. Symptomatic patients with coronary artery disease admitted for coronary angiography and angioplasty (PCI) were consecutively enrolled in this study. 249 consecutive patients underwent coronary artery stenting for stable angina (n=215) or non-ST-elevation acute coronary syndrome (n=34). Inhibition of platelet aggregation was assessed by MEA. Genetic polymorphism of CYP2C19 was tested by HRM Real-Time PCR method in 150 patients. Patients with HTPR were more frequently diagnosed with ischemic stroke (p=0.0351, OR=16.818, 95% CI [1.464-193.23]) and other ischemic cerebral events (stroke or TIA, p=0.0339, OR=6.5, 95% CI [1.36-31.07]). Cumulative assessment of all ischemic and ...Continue Reading
References
Nov 8, 2003·Stroke; a Journal of Cerebral Circulation·Chelsea S Kidwell, Steven Warach
Jun 9, 2004·Circulation·Shlomi MatetzkyHanoch Hod
Nov 7, 2006·Journal of the American College of Cardiology·Willibald HochholzerFranz-Josef Neumann
Dec 2, 2006·Thrombosis and Haemostasis·Orsolya TóthWolfgang Siess
Feb 12, 2008·European Heart Journal·Matthew J PricePaul S Teirstein
Mar 10, 2009·The American Journal of Cardiology·Betti GiustiGian Franco Gensini
Jun 3, 2009·Circulation·Ana PenaGilles Montalescot
Jun 11, 2010·BMC Medical Genetics·Diogo G B SantosAlexandre C Pereira
Jul 29, 2010·Thrombosis and Haemostasis·Claire Bal Dit SollierLudovic Drouet
Sep 11, 2010·Journal of the American College of Cardiology·Laurent BonelloUNKNOWN Working Group on High On-Treatment Platelet Reactivity
Feb 15, 2011·Current Vascular Pharmacology·Jayashree ShankerVijay V Kakkar
May 20, 2011·Thrombosis Research·Tong Yin, Toshiyuki Miyata
Dec 29, 2011·JAMA : the Journal of the American Medical Association·Michael V HolmesJuan P Casas
Jan 21, 2012·Journal of Thrombosis and Haemostasis : JTH·J M Siller-MatulaB Jilma
Mar 1, 2012·European Heart Journal·Inna Y GongRichard B Kim
Mar 28, 2012·European Heart Journal·Deepak L BhattUNKNOWN CHARISMA Investigators
Jun 5, 2012·International Journal of Cardiology·Jolanta M Siller-MatulaGünter Christ
Aug 25, 2012·Platelets·Paul Harrison
Jul 26, 2013·Thrombosis and Haemostasis·Jolanta M Siller-Matula, Bernd Jilma
Jul 31, 2013·Lancet·Gregg W StoneUNKNOWN ADAPT-DES Investigators
May 20, 2014·The American Journal of Cardiology·Nevio TaglieriClaudio Rapezzi
Oct 10, 2014·Expert Opinion on Pharmacotherapy·Udaya S TantryPaul A Gurbel
Citations
Aug 10, 2016·International Journal of Cardiology·Xiaorong XuXinchun Yang
Jul 2, 2016·British Journal of Clinical Pharmacology·Jolanta M Siller-MatulaIrene M Lang
Feb 17, 2017·European Heart Journal. Cardiovascular Pharmacotherapy·Max-Paul WinterJolanta M Siller-Matula
Jul 15, 2016·American Journal of Therapeutics·Tomáš BolekMarián Mokáň
Apr 17, 2020·Journal of Clinical Medicine·Ceren EyiletenJolanta M Siller-Matula
Jul 16, 2020·Platelets·Mohitosh BiswasBaharudin Ibrahim
Dec 19, 2019·Frontiers in Cardiovascular Medicine·Małgorzata OstrowskaJolanta M Siller-Matula
Dec 10, 2016·BMC Cardiovascular Disorders·K KukulaA Witkowski
Jul 8, 2020·Medicine·Shujuan LiQi Zheng
Oct 10, 2020·The Pharmacogenomics Journal·Conti ValeriaFilippelli Amelia